Open Access

Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer

  • Authors:
    • Cédric Poyet
    • Thomas Hermanns
    • Qing Zhong
    • Eva Drescher
    • Daniel Eberli
    • Maximilian Burger
    • Ferdinand Hofstaedter
    • Arndt Hartmann
    • Robert Stöhr
    • Ellen C. Zwarthoff
    • Tullio Sulser
    • Peter J. Wild
  • View Affiliations

  • Published online on: September 9, 2015     https://doi.org/10.3892/ol.2015.3691
  • Pages: 2753-2760
  • Copyright: © Poyet et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In addition to conventional clinicopathological parameters, molecular markers are also required in order to predict the course of disease in patients with urothelial bladder cancer (BC). Little is known about fibroblast growth factor receptor 3 (FGFR3) immunoreactivity and the clinical significance it may possess with regard to BC. The present study aimed to investigate the immunoreactivity of FGFR3 in primary urothelial bladder tumours, with regard to clinicopathological features and FGFR3 mutation status. Tissue microarrays were used to immunohistochemically analyse FGFR3 expression in 255 primary, unselected patients with BC. FGFR3 mutations were detected using SNaPshot analysis. Positive FGFR3 immunoreactivity was identified in 113/207 analysable cases (54.6%), and was significantly associated with FGFR3 mutation (P<0.001), low tumour stage (P<0.001), low histological grade (P<0.001) and a papillary growth pattern (P<0.001). Positive FGFR3 immunostaining (P=0.002) and FGFR3 mutation (P=0.002) were found to be significantly associated with increased disease‑specific survival following univariate analysis, demonstrating a median follow‑up period of 75 months. Using multivariate analyses, FGFR3 immunoreactivity was found not to be independent of classical pathological parameters. Immunohistochemical expression of FGFR3 is an early occurrence during the carcinogenesis of papillary non‑invasive BC. The presence of FGFR3 immunoreactivity in non‑invasive papillary urothelial carcinomas may be utilised as an indicator of tumours possessing low-grade features and good prognosis.
View Figures
View References

Related Articles

Journal Cover

November 2015
Volume 10 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Poyet, C., Hermanns, T., Zhong, Q., Drescher, E., Eberli, D., Burger, M. ... Wild, P.J. (2015). Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer. Oncology Letters, 10, 2753-2760. https://doi.org/10.3892/ol.2015.3691
MLA
Poyet, C., Hermanns, T., Zhong, Q., Drescher, E., Eberli, D., Burger, M., Hofstaedter, F., Hartmann, A., Stöhr, R., Zwarthoff, E. C., Sulser, T., Wild, P. J."Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer". Oncology Letters 10.5 (2015): 2753-2760.
Chicago
Poyet, C., Hermanns, T., Zhong, Q., Drescher, E., Eberli, D., Burger, M., Hofstaedter, F., Hartmann, A., Stöhr, R., Zwarthoff, E. C., Sulser, T., Wild, P. J."Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer". Oncology Letters 10, no. 5 (2015): 2753-2760. https://doi.org/10.3892/ol.2015.3691